Alpha-lipoic acid inhibits lung cancer growth via mTOR-mediated autophagy inhibition

FEBS Open Bio. 2020 Apr;10(4):607-618. doi: 10.1002/2211-5463.12820. Epub 2020 Mar 18.

Abstract

Lung cancer is the leading cause of cancer-related death, and there remains a need for novel therapies for this malignancy. Here, we examined the effects of alpha-lipoic acid (LA), a drug used for treating human diabetic complications, on lung cancer growth. We report that LA limited lung cancer growth in xenograft mice and reduced lung cancer A549 cell viability. We observed autophagy activation in human lung cancers, and report that LA inactivated autophagy in A549 cells. In addition, LA activated mammalian target of rapamycin (mTOR)/p70S6K signaling. Inhibition of mTOR with rapamycin reversed LA-induced inactivation of autophagy and abolished LA-induced suppression of A549 cell viability. Altogether, the data suggest that LA exerts an anti-lung cancer effect through mTOR-mediated inhibition of autophagy, and thus LA may have therapeutic potential for lung cancer management.

Keywords: alpha-lipoic acid; autophagy; lung cancer; mammalian target of rapamycin; rapamycin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / metabolism*
  • Adenocarcinoma of Lung / pathology
  • Administration, Oral
  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Autophagy / drug effects*
  • Cell Proliferation / drug effects*
  • Cell Survival / drug effects
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Mice
  • Mice, Nude
  • Signal Transduction / drug effects*
  • TOR Serine-Threonine Kinases / metabolism*
  • Thioctic Acid / administration & dosage*
  • Treatment Outcome
  • Tumor Burden / drug effects*
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Thioctic Acid
  • MTOR protein, human
  • TOR Serine-Threonine Kinases